Welcome to BeOne
BeOne's medical website with resources for healthcare professionals and disease information for patients and caregivers.
EHA2021
European Hematology Association
Related
This factsheet provides a useful summary of esophageal squamous cell carcinoma (ESCC). You will find valuable insights into epidemiology data, risk factors, symptoms, prognosis, diagnosis, and management and treatment options, all in an easy-to-read, downloadable format.
This factsheet provides a useful summary of non-small cell lung cancer (NSCLC). You will find valuable insights into epidemiology data, risk factors, symptoms, prognosis, diagnosis, and management and treatment options, all in an easy-to-read, downloadable format.
This book provides an overview of the current knowledge on the pathophysiology, epidemiology and etiology of Waldenström’s macroglobulinemia (WM) and discusses how the disease may present, how it is diagnosed and when treatment should be initiated. An outline of current approaches to treatment as well as ongoing and planned research directions is also included. It contains a wealth of information for all members of the multidisciplinary team who care for patients with WM in the fields of hematology, oncology, gerontology, pathology and neurology.
This book provides an overview of the current knowledge on the epidemiology, etiology, diagnosing and staging of chronic lymphocytic leukemia (CLL), as well as the molecular and genetic aspects that underpin treatment and prognosis. It provides a concise overview of treatment options, in both the front-line and relapsed/refractory settings, with particular focus on the novel targeted agents that have overcome many adverse prognostic factors and improved overall survival. This resource will provide all members of the multidisciplinary team who care for patients with CLL with a strong foundation for understanding, diagnosing and managing CLL in the present and future.
This book provides an overview of marginal zone lymphoma (MZL) for healthcare professionals and others with an interest in this blood cancer. It summarizes what is known about the pathophysiology of the disease, and discusses the importance of accurate diagnosis, staging, and prognosis, together with existing approaches to treatment and monitoring, including the latest evidence for new therapies in the relapsed/refractory (R/R) setting. With an eye to the future, it also reviews some of the therapies in development, which may ultimately improve quality of life and ensure better outcomes for patients with MZL.
